Literature DB >> 33112553

Impact of Bone Marrow Natural Killer Cells (NK); Soluble TNF-α and IL-32 Levels in Myelodysplastic Syndrome Patients.

Salah Aref1, Nada Khaled1, Abdel Hady Al Gilany2, Mohamed Ayed1, Tarek Abouzeid3, Doaa Attia1.   

Abstract

BACKGROUND: Myelodysplastic syndromes (MDS) are complex clonal hemopoietic progenitor cell disorders that result from the evolution of aberrant clones which lead to leukemia. Disorders of the immune system serve important functions in the pathophysiology and progression of this disorder. This study aimed to assess the bone marrow natural killer cells percentage as well as soluble TNF-α and sIL-32 concentration levels in MDS patients.
METHODS: Bone marrow samples were obtained from 34 MDS; 12 MDS-AML and 10 controls. The percentage of total NK cells and mature NK cells were determined by flowcytometry. Bone Marrow soluble TNF-α and sIL-32 concentration levels were measured by ELISA.
RESULTS: The percentage of total NK and mature NK cells were significantly lower in MDS patients as compared to controls (p.

Entities:  

Keywords:  AML; MDS; NK cells; sIL32; sTNF-α

Mesh：

Substances：

Year:  2020        PMID： 33112553      PMCID： PMC7798173          DOI： 10.31557/APJCP.2020.21.10.2949

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN： 1513-7368


  22 in total

1.  Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.

Authors:  Cyril Fauriat; Sylvaine Just-Landi; Françoise Mallet; Christine Arnoulet; Danielle Sainty; Daniel Olive; Regis T Costello
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

2.  Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia.

Authors:  Régis T Costello; Simona Sivori; Emanuela Marcenaro; Marina Lafage-Pochitaloff; Marie-Joelle Mozziconacci; Denis Reviron; Jean-Albert Gastaut; Daniela Pende; Daniel Olive; Alessandro Moretta
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

3.  Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.

Authors:  Andreas T Björklund; Mattias Carlsten; Ebba Sohlberg; Lisa L Liu; Trevor Clancy; Mohsen Karimi; Sarah Cooley; Jeffrey S Miller; Monika Klimkowska; Marie Schaffer; Emma Watz; Kristina Wikström; Pontus Blomberg; Björn Engelbrekt Wahlin; Marzia Palma; Lotta Hansson; Per Ljungman; Eva Hellström-Lindberg; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Clin Cancer Res       Date:  2018-02-14       Impact factor: 12.531

Review 4.  Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?

Authors:  Beatriz Sanchez-Correa; Carmen Campos; Alejandra Pera; Juan M Bergua; Maria Jose Arcos; Helena Bañas; Javier G Casado; Sara Morgado; Esther Duran; Rafael Solana; Raquel Tarazona
Journal:  Cancer Immunol Immunother       Date:  2015-06-10       Impact factor: 6.968

5.  Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

Authors:  Rizwan Romee; Maximillian Rosario; Melissa M Berrien-Elliott; Julia A Wagner; Brea A Jewell; Timothy Schappe; Jeffrey W Leong; Sara Abdel-Latif; Stephanie E Schneider; Sarah Willey; Carly C Neal; Liyang Yu; Stephen T Oh; Yi-Shan Lee; Arend Mulder; Frans Claas; Megan A Cooper; Todd A Fehniger
Journal:  Sci Transl Med       Date:  2016-09-21       Impact factor: 17.956

6.  Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.

Authors:  N Aggarwal; S H Swerdlow; S P TenEyck; M Boyiadzis; R E Felgar
Journal:  Cytometry B Clin Cytom       Date:  2016-02-03       Impact factor: 3.058

Review 7.  Chronic immune response dysregulation in MDS pathogenesis.

Authors:  Laura Barreyro; Timothy M Chlon; Daniel T Starczynowski
Journal:  Blood       Date:  2018-08-13       Impact factor: 22.113

8.  Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.

Authors:  Pearlie K Epling-Burnette; Fanqi Bai; Jeffrey S Painter; Dana E Rollison; Helmut R Salih; Matthias Krusch; Jianxiang Zou; Edna Ku; Bin Zhong; David Boulware; Lynn Moscinski; Sheng Wei; Julie Y Djeu; Alan F List
Journal:  Blood       Date:  2007-03-06       Impact factor: 22.113

Review 9.  Bone Marrow Immunity and Myelodysplasia.

Authors:  Claude Lambert; Yuenv Wu; Carmen Aanei
Journal:  Front Oncol       Date:  2016-07-20       Impact factor: 6.244

Review 10.  Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.

Authors:  Mattias Carlsten; Marcus Järås
Journal:  Front Immunol       Date:  2019-10-11       Impact factor: 7.561
View more
  2 in total

Review 1.  Inflammatory Cytokines Shape an Altered Immune Response During Myeloid Malignancies.

Authors:  Virginia Camacho; Valeriya Kuznetsova; Robert S Welner
Journal:  Front Immunol       Date:  2021-11-03       Impact factor: 7.561

Review 2.  The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification.

Authors:  Xiaohuan Peng; Xiaofeng Zhu; Tianning Di; Futian Tang; Xiaojia Guo; Yang Liu; Jun Bai; Yanhong Li; Lijuan Li; Liansheng Zhang
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.